Literature DB >> 11285068

Bone mineral density in children with cerebral palsy.

H A Tasdemir1, M Buyukavci, F Akcay, P Polat, A Yildiran, C Karakelleoglu.   

Abstract

BACKGROUND: The purpose of the present study was to evaluate the severity of and factors related to osteopenia in children with cerebral palsy (CP).
METHODS: Bone mineral density (BMD), calcium (Ca), phosphate (P), alkaline phosphatase (ALP), creatinine, parathyroid hormone (PTH) and 25-hydroxy vitamin D3 (25OHD3) concentrations were determined in 24 children with CP (15 ambulant, nine non-ambulant), aged between 10 months and 12 years (mean (+/-SD) 4.1+/-2.9 years). These vaules were compared with data obtained from a control group.
RESULTS: Adjusted mean BMD values were lower in the patient group than in controls (P<0.05). However, there was no difference between BMD values of ambulant and non-ambulant patients. The Ca and P levels of the patient group were significantly higher than those of controls (P<0.05).
CONCLUSIONS: The present study showed that BMD was decreased in all children with CP, but to a greater extent in non-ambulant children with CP, and immobilization is the major effective factor on bone mineralization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285068     DOI: 10.1046/j.1442-200x.2001.01352.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  11 in total

1.  Osteopenia in children with cerebral palsy can be treated with oral alendronate.

Authors:  Muhammet Sukru Paksu; Sebahattin Vurucu; Abdulbaki Karaoglu; Alper Ozgur Karacalioglu; Ahmet Polat; Ozgur Yesilyurt; Bulent Unay; Ridvan Akin
Journal:  Childs Nerv Syst       Date:  2011-09-18       Impact factor: 1.475

2.  Effect of high-frequency, low-magnitude vibration on bone and muscle in children with cerebral palsy.

Authors:  Tishya A L Wren; David C Lee; Reiko Hara; Susan A Rethlefsen; Robert M Kay; Frederick J Dorey; Vicente Gilsanz
Journal:  J Pediatr Orthop       Date:  2010 Oct-Nov       Impact factor: 2.324

3.  Choline kinase β mutant mice exhibit reduced phosphocholine, elevated osteoclast activity, and low bone mass.

Authors:  Jasreen Kular; Jennifer C Tickner; Nathan J Pavlos; Helena M Viola; Tamara Abel; Bay Sie Lim; Xiaohong Yang; Honghui Chen; Robert Cook; Livia C Hool; Ming Hao Zheng; Jiake Xu
Journal:  J Biol Chem       Date:  2014-12-01       Impact factor: 5.157

4.  Bone density and size in ambulatory children with cerebral palsy.

Authors:  Tishya Al Wren; David C Lee; Robert M Kay; Frederick J Dorey; Vicente Gilsanz
Journal:  Dev Med Child Neurol       Date:  2010-12-17       Impact factor: 5.449

5.  Bone mineral density and insulin-like growth factor-1 in children with spastic cerebral palsy.

Authors:  H Nazif; R Shatla; R Elsayed; E Tawfik; N Osman; S Korra; A Ibrahim
Journal:  Childs Nerv Syst       Date:  2017-02-24       Impact factor: 1.475

6.  A randomised controlled trial of standing programme on bone mineral density in non-ambulant children with cerebral palsy.

Authors:  J M Caulton; K A Ward; C W Alsop; G Dunn; J E Adams; M Z Mughal
Journal:  Arch Dis Child       Date:  2004-02       Impact factor: 3.791

Review 7.  Bone and skeletal muscle: Key players in mechanotransduction and potential overlapping mechanisms.

Authors:  Craig A Goodman; Troy A Hornberger; Alexander G Robling
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

Review 8.  Bone and skeletal muscle: neighbors with close ties.

Authors:  Douglas J DiGirolamo; Douglas P Kiel; Karyn A Esser
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

9.  Disrupted Bone Metabolism in Long-Term Bedridden Patients.

Authors:  Keiko Eimori; Naoto Endo; Seiji Uchiyama; Yoshinori Takahashi; Hiroyuki Kawashima; Kei Watanabe
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

10.  Quantifying bone marrow fat using standard T1-weighted magnetic resonance images in children with typical development and in children with cerebral palsy.

Authors:  Chuan Zhang; Jill M Slade; Freeman Miller; Christopher M Modlesky
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.